BioNexus Gene Lab (BGLC) Common Equity (2018 - 2026)

BioNexus Gene Lab's Common Equity history runs 9 years deep, the most recent figure standing at $8.1 million for Q1 2026.

• In Q1 2026, Common Equity rose 4.14% year-over-year to $8.1 million; the TTM figure through Mar 2026 stood at $8.1 million (up 4.14% YoY), while the FY2025 annual figure was $8.6 million, up 3.51% from the prior year.
• Common Equity came in at $8.1 million for Q1 2026 at BioNexus Gene Lab, down from $8.6 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $9.7 million in Q4 2023 to a low of $5.6 million in Q2 2023.
• A 5-year average of $7.8 million and a median of $7.8 million in 2025 frame the typical range for Common Equity.
• Across the five-year window, Common Equity soared 70.7% in 2024 and dropped 27.4% in 2025, its largest moves.
• BioNexus Gene Lab's Common Equity stood at $6.7 million in 2022, then jumped by 44.9% to $9.7 million in 2023, then slipped by 13.82% to $8.3 million in 2024, then climbed by 3.51% to $8.6 million in 2025, then retreated by 6.06% to $8.1 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $8.1 million, $8.6 million, and $6.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison